Beyond the Hype: Digital Therapeutics Delivering Personalised Healthcare

Opinion by Dr. Tim Ting-Yi Lin, MD, PhD, Medical Product Lead, Arcondis

Digital therapeutics are transforming healthcare by turning smartphones and wearables into personalised treatment tools, breaking down access barriers, and proving what real-time data can deliver. Better outcomes—anytime, anywhere.

The rise of digital therapeutics

The widespread adoption of smartphones and wearable devices has created fertile ground for digital therapeutics (DTx), a technology-driven approach to managing patient health, particularly for chronic conditions and mental health. DTx enables continuous health monitoring together with real-time data analysis, which facilitates personalised healthcare solutions and interventions, thus improving patients’ awareness and outcomes.

Additionally, DTx facilitates patient-centered care by transcending geographic boundaries and addressing limitations in healthcare resources, accessibility barriers, and provider availability, ultimately improving patient outcomes and alleviating strain on the healthcare system.

The introduction of DTx into the healthcare mainstream is facilitated by a maturing set of regulations that acknowledge and authorise these technologies. In combination with the newfound data on clinical outcomes that the era of DTx has ushered in, this also serves to validate and normalise its role in the healthcare ecosystem.

The growing market and established evidence

The digital therapeutics market has experienced remarkable growth, attracting significant investment over the past decade. While 2021 marked a peak with a total investment of nearly $60 billion¹, the market continues to show robust momentum². This sustained capital growth highlights the growing recognition of DTx’s value proposition and their potential to transform healthcare, captivating the attention of stakeholders across the industry.

The growing burden of behavioural health, mental health, dementia, and chronic illnesses challenge millions, and the magnitude of this challenge is staggering. The current healthcare landscape often falls short in providing multifaceted care and addressing complex long-term behavioral and mental health needs. One of the main barriers is the shortfall of continuous support and multifaceted approach needed for these conditions. Mental and behavioral health challenges require ongoing monitoring and self-management strategies. Traditional therapy sessions, while crucial, often lack the frequency needed to provide this continuous support. The gap between clinical visits can leave individuals vulnerable to setbacks and struggling to maintain progress. This gap can be closed with high-quality digital therapeutics, generating massive value for healthcare systems.

Unlike medications with immediate physiological effects, the effects of DTx often manifest subtly and gradually, influenced by a complex interplay of behavioural, environmental, and even social factors. Designing studies that convincingly demonstrate DTx efficacy requires innovative approaches. Adaptive trial designs, long-term follow-up, and the use of relevant surrogate endpoints can help capture these slower-burning effects. This inherent complexity makes it challenging to design studies that convincingly demonstrate their efficacy, particularly within the traditional evidence-based frameworks that regulators and healthcare professionals rely on.

The German DiGA program, while pioneering in its approach to DTx reimbursement, has also highlighted the difficulties in assessing and validating these novel interventions⁷. Concerns regarding the perceived low effectiveness and insufficient evidence for certain DiGAs, especially those provisionally listed, underscore the need for innovative trial designs and robust outcome measures.

To navigate these complexities, innovative approaches must be adopted. Adaptive trial designs, allowing for modifications during the study based on emerging data, can optimise the evaluation of DTx interventions. Long-term follow-up studies are essential to capture the sustained impact of DTx, as their benefits often unfold over extended periods. Furthermore, leveraging relevant surrogate endpoints, which are measurable indicators that predict clinical outcomes, can provide valuable insights into the effectiveness of DTx, even when direct clinical endpoints are challenging to assess.

Additionally, establishing a clear and quantifiable link between DTx interventions and specific biological changes is another hurdle and requires sophisticated research. Unlike traditional pharmaceuticals, where the impact on biological pathways is often more evident, attributing a desired outcome solely to a DTx intervention is inherently complex. This complexity can make it difficult to gain acceptance from regulators and healthcare professionals who traditionally rely on biological mechanisms to validate treatments. The expansion of Germany’s DiGA program to include higher-risk medical devices further raises the bar for evidence standards, necessitating rigorous studies, such as prospective comparative trials⁷. Developing robust biomarkers, which are biological indicators of disease or treatment response, can help bridge this gap and provide tangible evidence of DTx’s impact on the underlying biological processes.

Finally, the vast amount of personal health data collected by DTx raises a dual challenge: safeguarding patient privacy while harnessing the potential of real-world data (RWD) and evidence (RWE). Any breach or misuse of this sensitive information can severely erode patient trust and lead to legal repercussions.

When handled responsibly and ethically, this wealth of RWD generated by DTx offers unprecedented opportunities for generating RWE, enabling continuous assessment of product effectiveness, safety, and value in real-world settings. Balancing the need for data collection and robust privacy protections is a constant challenge.

A multifaceted approach is needed to address these challenges. By leveraging the unique strengths of DTx while proactively addressing their limitations, we can unlock their full potential to improve patient outcomes and transform healthcare delivery. As the field matures, continued collaboration between stakeholders will be critical to realising the promise of digital therapeutics.

Reimbursement strategies for digital therapeutics

Traditional reimbursement models, primarily designed for pharmaceutical drugs and medical devices, often struggle to accommodate the unique value proposition of DTx. This results in a fragmented landscape with varying coverage policies and payment mechanisms across different countries and healthcare systems^{7, 11}. The German DiGA program, with its fast-track pathway and automatic reimbursement for listed DTx products, stands out as a notable exception. However, even within this progressive framework, there are ongoing discussions surrounding the cost-effectiveness and evidence requirements for reimbursement. The recent legislative changes, including the shift towards performance-based reimbursement from 2026 onwards, highlight the ongoing efforts to refine and optimise DTx reimbursement models.

The DTx reimbursement landscape is still in its early stages, but rapidly evolving. As the evidence base for DTx grows and innovative reimbursement models emerge, the potential for these digital solutions to transform healthcare and improve patient outcomes is immense. By addressing the challenges and opportunities outlined above, DTx developers, payers, and policymakers can collaborate to create a sustainable and equitable reimbursement system that supports the widespread adoption of these innovative solutions.

Future projection

Digital therapeutics represent a transformative shift in the healthcare landscape, offering innovative solutions to some of the most pressing health challenges. The future of DTx lies in pushing boundaries and exploring novel approaches to treatment delivery. As technology continues to advance, the potential for DTx to improve patient outcomes, enhance treatment personalisation, and reduce healthcare costs becomes increasingly evident. Integrating emerging technologies such as virtual reality, augmented reality, and wearable sensors can create immersive and interactive therapeutic experiences that enhance engagement and improve outcomes.

Developing DTx for underserved populations and addressing health disparities through equitable access and culturally sensitive design is another critical area for innovation. However, the successful integration of digital therapeutics into mainstream healthcare requires careful consideration of both their benefits and challenges. As Arcondis, we help guide the development and implementation of effective digital therapeutics, ultimately contributing to a healthier, more connected world.